GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.
about
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression.Brief isoflurane anesthesia regulates striatal AKT-GSK3β signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease.Ketamine and its metabolite (2R,6R)-hydroxynorketamine induce lasting alterations in glutamatergic synaptic plasticity in the mesolimbic circuit.Eradicating Suicide at Its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors
P2860
GSK-3: A key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
GSK-3: A key regulatory target ...... anced AMPA to NMDA throughput.
@en
GSK-3: A key regulatory target ...... anced AMPA to NMDA throughput.
@nl
type
label
GSK-3: A key regulatory target ...... anced AMPA to NMDA throughput.
@en
GSK-3: A key regulatory target ...... anced AMPA to NMDA throughput.
@nl
prefLabel
GSK-3: A key regulatory target ...... anced AMPA to NMDA throughput.
@en
GSK-3: A key regulatory target ...... anced AMPA to NMDA throughput.
@nl
P2860
P356
P1433
P1476
GSK-3: A key regulatory target ...... anced AMPA to NMDA throughput.
@en
P2093
Carlos A Zarate
P2860
P304
P356
10.1111/BDI.12452
P577
2016-11-29T00:00:00Z